Schering AG v. megalonamia
WIPO Case No. D2002-0229
- Outcome
- Transfer
- Domain names
- advantan.com
- Complainant
- Schering AG
- Respondent
- megalonamia
- Panelist
- Knud Wallberg
- Decided
- 26 Apr 2002
- Language
- English
Source: WIPO Arbitration and Mediation Center. Official copy: https://www.wipo.int/amc/en/domains/decisions/html/2002/d2002-0229.html
WIPO Arbitration and Mediation Center
ADMINISTRATIVE PANEL DECISION
Schering AG v. Megalonamia (this domain is for sale)
Case No. D2002-0229
1. The Parties
Complainant is Schering AG, Berlin, Germany.
Respondent is Megalonamia (this domain is for sale), San Francisco, USA.
2. The Domain Name and Registrar
The domain name at issue is <advantan.com>
The Registrar is IHOLDINGS.COM, INC., Miami, USA.
3. Procedural History
A Complaint was submitted to the World Intellectual Property Organization Arbitration
and Mediation Center (the "WIPO Center") on March 8, 2002. The
WIPO Center sent an Acknowledgement of Receipt of Complaint to the Complainant
on March 15, 2002.
On March 15, 2002, a Request for Registrar Verification was transmitted
to the Registrar, and on March 21, 2002, the Registrar confirmed that
it was in receipt of the Complaint. The Registrar forwarded at the same time
the requested WHOIS details.
A Formal Requirements Compliance Checklist was completed by the WIPO Center
and the Panel has independently determined and agrees with the assessment of
the WIPO Center that the Complaint is in compliance with the requirements of
the Uniform Domain Name Dispute Resolution Policy ("the Policy") and
the Rules for Uniform Domain Name Dispute Resolution Policy ("the Rules"),
as approved by ICANN on October 24, 1999, and the WIPO Supplemental
Rules for Uniform Domain Dispute Resolution Policy (the "WIPO Supplemental
Rules"), in effect as of December 1, 1999. The Complainant paid
on time and in the required amount the fees for a single member Panel.
On March 22, 2002, a Notification of Complaint and Commencement of
Administrative Proceeding (the "Commencement Notification") was transmitted
to the Respondent by the required means, setting a deadline of April 11, 2002,
by which the Respondent could file a Response to the Complaint.
On April 5, 2002, the WIPO Center received the Response and sent
an Acknowledgement to that effect to the Respondent.
The WIPO Center then invited Mr. Knud Wallberg to serve as Panelist in the
case, and transmitted to him a Statement of Acceptance and Request for Declaration
of Impartiality and Independence.
Having received the Statement of Acceptance and Declaration of Impartiality
and Independence from Mr. Knud Wallberg, the WIPO Center transmitted on April 12, 2002,
to the parties a Notification of Appointment of Administrative Panel and the
Projected Decision Date.
The Panel finds that the Administrative Panel was properly constituted and
appointed in accordance with the Rules and WIPO Supplemental Rules.
Both parties have after the appointment of the Panel sent further submissions
to the Panel, the other party and the WIPO Center without being required to
do so by the Panel. The Panel has decided to disregard those submissions.
The Administrative Panel has thus issued its Decision based on the Complaint,
the Response, the Policy, the Rules, and the WIPO Supplemental Rules.
4. Factual Background
The following facts are taken from the Complaint:
The Complainant is a research-oriented pharmaceutical company based in Germany
with more than 150 subsidiaries and associated companies worldwide. With 23,700 employees,
Schering AG achieved a turnover of EUR 4,4 billion in the year 2000, 89 %
of this outside Germany. Its shares are listed in New York, London, Zurich,
Geneva, Basel, as well as in Frankfurt, Berlin, Dusseldorf, Hamburg and Munich.
A copy of the Complainant's annual report for the year 2000, was provided
as Annex C.
ADVANTAN the name of a dermatology product which is manufactured by the Complainant
and sold (in many countries) world-wide. In fact, ADVANTAN is one of the Complainant's
best-selling dermatology products with global sales of EUR 26 million in 2000.
The Complainant registered ADVANTAN as a trademark with the German Patent and
Trademark Office on January 22, 1988 (registration no. DT 1 116 927).
The trademark is registered for "pharmaceutical preparations, namely preparations
for the treatment of skin inflammations and/or allergic skin diseases"
(class 05). A copy of the relevant trademark certificate was provided as Annex
D.
Based on this German trademark, an International Registration of the ADVANTAN
trademark has been certified by the World Intellectual Property Organization
on November 17, 1988. This trademark is registered for a large number
of countries. A copy of the original registration certificate and the relevant
printout of the "Romarin" trademark database were provided as Annexes E1
and E2.
Furthermore, the Complainant has registered ADVANTAN as a trademark with the
United States Patent and Trademark Office for "pharmaceutical preparations
for the treatment of inflammatory and/or allergic skin diseases" (class
05, US classes 06, 18, 44, 46, 51, 52). This trademark was registered
on August 19, 1997, with registration no. 2.880.959. A copy of this
trademark certificate was provided as Annex F.
The Complainant has registered, among others, the domain names <advantan.de>,
<advantan.net>, <advantan.info> & <advantan.biz> and is
currently preparing a website to present information about its product ADVANTAN
under these Internet addresses.
Respondent
Megalonamia was formed in January 2001, as a Sole Proprietorship by Gavin Atwood Coombs,
in the city of San Francisco, California, USA. Megalonamia is a brand identity
and naming firm. Namepharm and Alphabet Branding are subsidiary entities that
have not yet been registered as business entities.
The contested domain name was registered by Respondent on December 5, 2000.
5. Parties’ Contentions
A. Complainant
The following is taken from the Complaint:
The Domain Name is Identical or Confusingly Similar to Complainant’s Mark
The various "ADVANTAN" trademarks registered to the Complainant as
described above are essentially identical to the disputed domain name, as required
by para. 4(a)(i) UDRP.
The only difference between the <advantan.com> domain name and the "ADVANTAN"
trademark is the suffix ".com", an irrelevant distinction which does
not change the likelihood of confusion. The term ".com" means "commercial
institution" and is meant to distinguish commercial sites. It is merely
the classification of the purpose for which the domain name is being used. Therefore,
the domain name <advantan.com> is essentially identical to the Complainant's
registered trademarks for the purposes of this proceeding.
Respondent has no Legitimate Interest in the Domain Name
The Respondent has no rights or legitimate interests to the domain name.
The Respondent is not using, and has conceded that he is currently not planning
to use, the domain name or a name corresponding to the domain name in connection
with a bona fide offering of goods or services. The website currently displayed
at "http://www.advantan.com" is a standard website provided by the
Respondent's Registrar. In his various letters to the Complainant Mr. Coombs
has repeatedly confirmed that he has no projects for which he intends to use
the Domain <advantan.com>, and that he does not see any such projects
for the immediate future.
The Respondent (as an individual, business, or other organization) has never
been commonly known by the name "ADVANTAN" or by any name remotely
similar to "ADVANTAN". The Respondent is not, and never has been,
representative or licensee of the Complainant, nor is the Respondent otherwise
authorized to use the Complainant's trademarks.
Furthermore, the Respondent is not making a legitimate non-commercial or fair
use of the domain name. The Respondent has conceded that the Domain <advantan.com>
was registered for commercial purposes. According to Mr. Coombs various
letters and the Respondent's websites at "http://www.namepharm.com"
and "http://www.namepharm.com", the Respondent has registered several
thousand .com URL’s held specifically for pharmaceuticals, to be used for the
"clients" of Mr. Coombs' brand agency.
In a previous administrative Panel decision, it has been held that the mere
speculative idea for a bona fide business application of a generic domain
name does not fall within any of the circumstances listed under para. 4 (a)
UDRP as evidence of rights or legitimate interests. The mere speculation in
generic domain names without showing any demonstrable evidence of plans
for a bona fide use is not sufficient to prove legitimate interests in a domain
name. Speculation itself is not recognized under the UDRP as a legitimate interest
and the UDRP should not be interpreted to hold that mere speculation in domain
names is a legitimate interest. See Libro AG v. Na Global Link Ltd.,
WIPO case No. D2000-0186.
This disapproval of speculative domain registrations not only holds for generic
domain names, but is particularly true for domain names identical to registered
and - within the pharmaceutical sector - world-famous trademarks. In fact, the
entire UDRP would rendered useless if any potential future use by the Respondent
could be seen as a right or legitimate interest in the domain name. For this
reason, para. 4(c)(i) asks for demonstrable preparations (and not just vague
speculations) to use the domain name in order to assume a right or legitimate
interest.
Respondent Registered and is Using the Domain Name in Bad Faith
The Respondent has registered and is using the domain name in bad faith.
According to para. 4(b)(i) UDRP, the following shall be evidence of the registration
and use of a domain name in bad faith:
"Circumstances indicating that the Respondent has registered (...) the
domain name primarily for the purpose of selling (...) the domain name registration
to the Complainant who is the owner of a trade mark (...), for valuable consideration
in excess of the Respondent's documented out-of-pocket costs directly related
to the domain name."
The requested price of US$ 12,000 is clearly in excess of the Respondents'
out-of-pocket costs directly related to the Domain <advantan.com>.
The registration in the name of "megalonamia (this domain is for sale)"
alone is sufficient to prove that the Respondent registered the Domain <advantan.com>
only for the purpose of selling it.
Given the Complainant's U.S. trademark ADVANTAN described above, the Respondent
had constructive notice of this trademark registration as a matter of the United
States trademark law pursuant to 17 U.S.C. 1072.
See WIPO Administrative Panel Decisions, J. Crew International, Inc v. crew.com,
case No. D2000-0054.
The Respondent had first registered the domain name <advantan.com> on
December 5, 2000, well after the registration of the Complainant's
trademark ADVANTAN on August 19, 1997. The Respondent (that is Mr. Coombs)
operates a pharmaceutical brand agency specialized on "trademark screening"
and the registration and sale of Internet domain names. This is sufficient evidence
to conclude that the Respondent knew (or should have known) of the Complainant's
ADVANTAN trademark at the time he registered the domain name <advantan.com>.
In previous administrative Panel decisions it has been held that Respondent's
knowledge of Complainant's trademark at the time of registration of the domain
name is sufficient to suggest bad faith.
See WIPO Administrative Panel Decisions, Expedia Inc. v. European Travel
Network, case No. D2000-0137; E.
& J. Gallo Vinery v. Oak & Westmint Group, case
No. D2000-1213; National Arbitration Forum Decision, Pepsi Co, Inc. v.
Datasphere Ltd., case No. FA0102000096695.
Furthermore, in his letter of May 23, 2001, enclosed as Annex L,
the Respondent has explicitly confirmed that he had positive knowledge of the
Complainant's US trademark ADVANTAN. In spite of this knowledge, the Respondent
wrote in his letter of August 16, 2001 (Annex M), that he "will
be reserving <advantan.com> again soon". This, and the repeated offers
to sell the Domain to the Complainant sufficiently prove that the Domain was
registered (and renewed) primarily for the purpose of selling it to the Complainant
pursuant to para. 4(b)(i) UDRP.
Furthermore, the Respondent is intentionally attempting to attract, for commercial
gain, Internet users to the website currently operated at "http://www.advantan.com"
by creating a likelihood of confusion with the Complainant's mark as to the
source, sponsorship, affiliation, or endorsement of this website. This is additional
evidence of bad faith registration and use pursuant to para. 4(b)(iv) UDRP.
In fact, the Respondent is currently diverting Internet users searching for
online information on the Complainant’s ADVANTAN product to the online casinos
and gambling websites, which are currently advertised at "http://www.advantan.com".
It has already been held by an administrative Panel decision that such diversion
to virtual casino gambling sites must be considered to be for commercial purposes
pursuant to para. 4(b)(iv) UDRP.
See Administrative Panel Decisions, Inter-IKEA. v. Polanski, WIPO
case No. D2000-1614, provided as Annex [W], page 4.
B. Respondent
The following is taken from the Response:
Your domain name is identical or confusingly similar to a trademark or service
mark in which the Complainant has rights
This is the reason for Schering’s Complaint. We understand Schering’s frustration
that we created and registered the domain <advantan.com> on December 5, 2000,
before Schering thought or acted to register the domain. We have made reasonable
efforts to offer the domain to Schering resulting from our discovery on April 18, 2001,
several months after Megalonamia’s registration of <advantan.com>, that
Schering had registered <advantan.org> Our first communication to Schering
was via email on April 18, 2001, the same day we discovered Schering
had reserved <advantan.org>. On May 23, 2001, while researching
the background of the name Advantan as used by Schering, we discovered Schering’s
trademark interest in class 5. On this same date we contacted Schering’s trademark
attorney in New York City, referencing our discovery of Schering’s trademark
for an "Advantan" pharmaceutical product.
The registration of <advantan.org> and our discovery of Schering’s trademark
for Advantan in class 5 indicated to us that perhaps Schering would be interested
in using the <advantan.com> domain, a name and domain that we created
independent of any knowledge of the Schering product Advantan and through a
creative means that will be described in detail later in this document.
You have no rights or legitimate interests in respect of the domain name
Megalonamia does have a legitimate right, as we are a naming company. We created
the name Advantan on December 5, 2000, and registered <advantan.com>
the same day, among other names that we created that day, to use for future
client naming jobs and for our own purposes. Please see attachment B. I also
have a personal interest in the name "Advantan" and the <advantan.com>
domain, as I plan to form Advantan Real Estate Brokerage in California this
summer.
Your domain name has been registered and is being used in bad faith
Megalonamia created the name Advantan independent of any knowledge of Schering’s
Advantan pharmaceutical product, and we will provide material evidence to support
this fact later in this document. <advantan.com> and all other domain
names owned by Megalonamia have never been registered in bad faith. Both the
English and German languages are teutonic languages, so it is quite logical
to expect that the same name could be created by separate individuals or entities
independently of the other. Further, there is a popular saying that reminds
us that "there is nothing new under the sun." "Advance"
and "Advantage" are the English words/word stems that we used to create
names such as "Advancian" and "Advantan". This is how we
came to create the name "Advantan" and how we created all of the other
names that we have registered. English words/word stems + "branded"
endings.
6. Discussion and Findings
According to Paragraph 15(a) of the Rules, the Panel shall decide a Complaint
in accordance with the Policy, the Rules and any rules and principles of law
that it deems applicable.
Paragraph 4(a) of the Policy directs that the Complainant must prove each of
the following:
1) that the domain name registered by the Respondent is identical or confusingly
similar to a trademark or service mark in which the Complainant has rights;
and
2) that the Respondent has no rights or legitimate interests in respect of
the domain name; and
3) that the domain name has been registered and is being used in bad faith.
Identical or Confusingly Similar
The Complainant’s mark ADVANTAN is registered and has been used in many countries
around the world including in the home country of Respondent USA.
The domain name <advantan.com> contains the mark in its entirety with
the addition of the gTLD denomination .com.
The domain name is thus identical to the trademark in which the Complainant
has rights.
The requirements set out in the Policy, Paragraph 4(a)(i) are therefore fulfilled.
Legitimate Interest
The Complainant has not licensed or otherwise permitted the Respondent to use
its trademark or to apply for any domain name incorporating the mark.
Further, the Respondent has not demonstrated that he has any prior rights in
the domain name. No evidence has been put before the Panel that shows that Respondent
has made any demonstrable preparations to use the domain name before the filing
of the Complaint, or that he was commonly known by the domain name before that
time.
Respondent now claims that he intends to use the domain name for a real estate
brokerage that he intends to establish this summer. No concrete evidence on
these business activities has been provided, and this claim can thus not constitute
a defense for the purpose of these proceedings.
In addition, the Panel wants to note that this allegation or the fact that
Respondent has registered a series of other domain names, some of which may
not conflict with others trademark rights does not in itself constitute a legitimate
interest for the purpose of this case.
The requirements of the Policy, Paragraphs 4(a)(ii) are also considered fulfilled.
Bad Faith
Paragraph 4(a)(iii) of the Policy further provides that the Complainant must
prove registration and use of the domain name in bad faith. Paragraph
4(b) sets out, by way of example, the kind of evidence that may be put forward.
Respondent claims that he had no knowledge of Complainant’s mark when he registered
the domain name. The name was allegedly created and registered by Respondent
at the same time as a series of other coined names. However, it is undisputed
that Respondent approached Complainant and offered to sell the domain name and
that Respondent actually referred to Complainant’s trademark rights in the said
letter. No exact and credible information has been put forward by Respondent
that explains how this knowledge of Complainant’s rights came about, but since
Complainant’s mark was registered in the US at the time of the registration
of the contested domain name, the existence of the mark was public knowledge.
The Panel also notes that Respondent describes his business as a brand identity
and naming firm. In describing his business Respondent also says that he registers
domain names "to use for future client naming jobs or for our own purposes".
Respondent thus clearly indicates that he must have knowledge of how to "clear"
possible new names against existing rights including existing trademark rights.
Weighing the evidence before it the Panel therefore concludes that the Complainant
has proved that the Respondent was acting in bad faith pursuant to Paragraph
4(a)(iii) of the Policy. Reference is made to WIPO
Case D2000-0028 and WIPO Case D2001-1384.
7. Decision
In view of the above circumstances and facts the Panel finds that the domain
name registered by the Respondent is identical to the trademark in which the
Complainant has rights, that the Respondent does not have any rights or legitimate
interests in respect of the domain name, and that the domain name has been registered
and is being used in bad faith.
Consequently, the Panel decides that the domain name <advantan.com> be
transferred to the Complainant.
Knud Wallberg
Sole Panelist
Dated: April 26, 2002
More cases by this complainant
- Schering AG v. SmartBuy Corporation — D2004-1037 · menostar.com · Transfer · 21 Feb 2005
- Schering AG v. BNG Holdings — D2002-0743 · climara.com · Transfer · 01 Oct 2002